Methodological Approaches of a Pharmaceutical Company’s Commercial Policy Development in Order to Reduce Antitrust Risks
https://doi.org/10.37791/2687-0657-2025-19-1-52-77
Abstract
Within the framework of the publication the authors of the article defined the category of “commercial policy” and the conceptual thesaurus associated with it, summarized the basic legal requirements and recommendations of the Russian Federal Antimonopoly Service for the development and implementation of commercial policies of companies operating in the pharmaceutical and medical device markets, including those with a dominant position. A set of explanations of the regulatory framework, law enforcement practice in relation to manufacturers of medicines is presented, the most significant provisions of the Recommendations of the Federal Antimonopoly Service and the Code of Pharmaceutical Market Participants are systematized and highlighted. Based on the conducted research, which includes an audit of regulatory documents of pharmaceutical companies, systematization of data on the applied criteria for selecting and evaluating counterparties, economically sound recommendations are proposed on the hierarchy of requirements applied to counterparties in the pharmaceutical drugs and medical products market. A methodology for evaluating potential partners and existing counterparties has been developed and tested, which ensures non-discriminatory access to the market for participants, transparency and legitimacy of the decision-making procedure on the conclusion or termination of supply contracts. The structural and dynamic analysis of incentive payments made it possible to identify approaches to the formation of a fair and competitive system of discounts and incentive instruments.
About the Authors
I. V. Knyazeva
Siberian Institute of Management – Branch of RANEPA
Russian Federation
Russian Federation
Irina V. Knyazeva, Dr. Sci. (Econ.), Professor, Head of Center for Competition Policy and Economics,
Novosibirsk.
E. A. Shkulova
Russian Academy of National Economy and Public Administration
Russian Federation
Russian Federation
Elena A. Shkulova, Cand. Sci (Econ.), Lecturer at Marketing and Advertising Department, Institute of Management,
Moscow.
References
1. Avdasheva S., Kudrin A. Zadachi torgovykh politik chastnykh kompanii kak instrumenta regulirovaniya i razvitiya konkurentsii: mirovoi opyt i popytka prognoza [Objectives of trade policies of private companies as an instrument of regulation and competition: World experience and attempt to forecast]. Economicheskaya politika=Economic Policy, 2013, no.5, pp.106-126.
2. Akimova A. Torgovye politiki: argumenty za i protiv [Trade policy: Arguments for and against]. Konkurentsiya i pravo, 20.02.2015. Available at: https://cljournal.ru/vybor/111/ (accessed 02.11.2024).
3. Botnaryuk M. V., Timchenko T. N. The Russian pharmaceutical market: The main trends of development and pricing in modern conditions. Problemy socialnoi gigieny, zdravookhranenia i istorii mediciny=Problems of Social Hygiene, Public Health and History of Medicine, 2022, vol.30, no.2, pp.198-206 (in Russian). DOI: 10.32687/0869-866X-2022-30-2-198-206.
4. Dekhtyar I. Problemnye voprosy borby s narusheniyami antimonopolnogo zakonodatelstva na farmacevticheskom rynke [Problematic issues of combating violations of antimonopoly legislation in the Russian pharmaceutical market]. Aktualnye problemy administrativnogo i administrativno-processual’nogo prava (Sorokinskie chteniya): sbornik statei po materialam mezhdunarodnoi nauchno-prakticheskoi konferencii (Sankt-Peterburg, 24 marta 2023 g.) [Actual problems of administrative and administrative procedure law (Sorokin readings): Collection of articles based on the materials of the international scientific and practical conference (St. Petersburg, March 24, 2023)]. Ed. by A. I. Kaplunov, compiled by A. I. Kaplunov, A. O. Drozd, N. M. Kramarenko, E. Kh. Mamedov. St. Petersburg, 2023, pp.143-150 (in Russian).
5. Knyazeva I. The Scylla and Charybdis of Antitrust Enforcement in the Context of the SocioEconomic Crisis Caused by the COVID-19 Pandemic. Sovremennaya konkurentsiya=Journal of Modern Competition, 2020, vol.14, no.2(78), pp.5-25 (in Russian). DOI: 10.37791/1993-75982020-14-2-5-25.
6. Knyazeva I., Bondarenko I., Zaikin N. Implementation of a Discount Policy the Shortage B2B Markets: A Marketing Ploy or Price Discrimination? Sovremennaya konkurentsiya=Journal of Modern Competition, 2021, vol.15, no.4, pp.60-78 (in Russian). DOI: 10.37791/2687-0657-2021-15-4-60-78.
7. Knyazeva I., Dozmarov K. Antitrast Compliance Programme-Prevention of Risks of Violation of Competition Law by the Company. Eko=ECO, 2020, no.4(550), pp.110-129 (in Russian). DOI: 10.30680/ECO0131-7652-2020-4-110-129.
8. Knyazeva I., Zaikin N., Bondarenko I. The Price Discrimination on the Shortage Markets: Theoretical Analysis. Sovremennaya konkurentsiya=Journal of Modern Competition, 2021, vol.15, no.3, pp.71-85 (in Russian). DOI: 10.37791/2687-0657-2021-15-3-71-85.
9. Kodeks dobrosovestnykh praktik v farmatsevticheskoi otrasli (podgotovlen Rabochei gruppoi pod egidoi Komiteta Assotsiatsii evropeiskogo biznesa po zdravookhraneniyu i farmatsevtike 19 aprelya 2016 g.) [The Code of Good Practices in the Pharmaceutical Industry (was prepared by a Working Group under the auspices of the Association of European Businesses Committee on Healthcare and Pharmaceuticals on April 19, 2016]. FAS Rossii. Available at: https://fas.gov.ru/documents/562364 (accessed 22.10.2024) (in Russian).
10. Markov N., Yakimova E. Analysis of Competition and Dominance in the Russian Pharmaceutical Market. Farmakoekonomika: teoriya i praktika=Pharmacoeconomics: Theory and Practice, 2022, vol.10, no.4, pp.22-33 (in Russian). DOI: 10.30809/phe.4.2022.4.
11. Muravskaya E. Antimonopolnyi complains [Antitrust compliance]. Unost nauki: sbornik studencheskikh nauchnykh statei [Youth of Science: Collection of student scientific articles]. Ed. by N. I. Arkhipovoy; ed. board: E. V. Zenkina [et al.]. Moscow, Russian State Humanitarian University, 2022, pp.343-348 (in Russian).
12. Nadezhda Sharavskaya: Farmatsevticheskaya otrasl’ vsegda nakhoditsya v zone povyshennogo vnimaniya antimonopol’nykh organov [Nadezhda Sharavskaya: The pharmaceutical industry is always in the zone of increased attention of antimonopoly authorities]. FAS Rossii, 09.07.2020. Available at: https://fas.gov.ru/news/30088 (accessed 29.10.2024).
13. Numerova A., Denchenkova O. Correlation between private and public interests in antitrust regulation (as demonstrated by the pharmaceutical market). Rossiiskoe konkurentnoe parvo i ekonomika=Russian Competition Law and Economy, 2020, no.1(21), pp.18-25 (in Russian). DOI: 10.32686/2542-0259-2020-1-18-25.
14. Rekomendatsii FAS Rossii po razrabotke i primeneniyu kommercheskikh politik khozyaistvuyushchimi sub”ektami, zanimayushchimi dominiruyushchee polozhenie na rynkakh lekarstvennykh sredstv i rynkakh meditsinskikh izdelii (razrabotany Upravleniem kontrolya sotsial’noi sfery i torgovli Federal’noi antimonopol’noi sluzhby i odobrennye Prezidiumom FAS Rossii 17 iyunya 2015 goda) [Russian FAS Recommendations on the development and application of commercial policies by business entities that occupy a dominant position in the markets of medicines and medical devices (developed by the Department of Control of the Social Sphere and Trade of the Federal Antitrust Service and approved by the Presidium of the FAS of Russia on June 17, 2015)]. FAS Rossii. Available at: https://fas.gov.ru/documents/575620 (accessed 22.10.2024).
15. Sdvizhkov M. A. Antitrust compliance in the pharmaceutical industry: Problems and prospects of implementation. Rossiiskoe konkurentnoe parvo i ekonomika=Russian Competition Law and Economy, 2021, no.4(28), pp.52-59 (in Russian). DOI: 10.47361/2542-0259-2021-4-28-52-59.
16. Smirnova O., Agapova E., Elagina A. Antimonopolnoe regulirovanie cenovoi diskriminacii: normativnoe opredelenie i osobennosti vyyavleniya [Antimonopoly regulation of price discrimination: regulatory definition and features of detection]. Vestnik Samarskogo gosudarstvennogo ekonomicheskogo universiteta, 2015, no.6(128), pp.6-8 (in Russian).
17. Solodova R., Sokolova A. State regulation of medicines’ pricing in Russia – legislative framework, international overview and glimpse into the future. Sovremennaya organizaciya lekarstvennogo obespecheniya=Current Drug Supply Management, 2019, no.3, pp.11-18 (in Russian). DOI: 10.30809/solo.3.2019.2.
18. Stenogramma kruglogo stola «Posledstviya antimonopol’noi reglamentatsii torgovoi politiki chastnykh kompanii» (Moskva, 13 maya 2013 g.) / Analiticheskii tsentr pri Pravitel’stve RF [Transcript of the round table “Consequences of antimonopoly regulation of trade policy of private companies” (Moscow, May 13, 2013), Analytical Center under the Government of the Russian Federation]. Sovremennaya konkurentsiya=Journal of Modern Competition, 2013, no.3(39), pp.3-29 (in Russian).
19. Farmatsevticheskii rynok Rossii 2023 [Russian Pharmaceutical Market 2023]. DSM Group. Available at: https://dsm.ru/docs/analytics/Annual_report_2023_RUS_.pdf (accessed 16.11.2024).
20. Tsyganov A. G. Torgovye praktiki khozyaistvuushikh sub’ektov – napravlenie razvitiya konkurentnoi politiki [Trade practices of business entities – the direction of development of competition policy]. Ekonomicheskaya politika=Economic Policy, 2013, no.5, pp.73-80 (in Russian).
21. Global Medicine Spending and Usage Trends: Institute Report. IQVIA, 05.03.2020. Available at: https://www.iqvia.com/insights/the-iqvia-institute/reports/global-medicine-spending-and-usage-trends (accessed 26.10.2024).
Review
For citations:
Knyazeva I.V., Shkulova E.A. Methodological Approaches of a Pharmaceutical Company’s Commercial Policy Development in Order to Reduce Antitrust Risks. Journal of Modern Competition. 2025;19(1):52-77. (In Russ.) https://doi.org/10.37791/2687-0657-2025-19-1-52-77
Views:
7
Email this article 